(1998)
Therapeutic effi cacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
(1999)
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group, 353
R. Rau, G. Herborn, H. Menninger, O. Sangha (2002)
Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one-year double-blind study in 174 patients.Rheumatology, 41 2
M. Weinblatt, D. Reda, W. Henderson, A. Giobbie-Hurder, D. Williams, A. Diani, S. Docsa (1999)
Sulfasalazine treatment for rheumatoid arthritis: a metaanalysis of 15 randomized trials.The Journal of rheumatology, 26 10
A. Bennett, H. Marzo-Ortega, P. Emery, D. McGonagle (2009)
Diagnosing axial spondyloarthropathy. The new Assessment in SpondyloArthritis international Society criteria: MRI entering centre stageAnnals of the Rheumatic Diseases, 68
B. Combe, R. Landewé, C. Lukas, Horatio Bolosiu, F. Breedveld, M. Dougados, P. Emery, G. Ferraccioli, J. Hazes, Lars Klareskog, K. Machold, E. Martı́n-Mola, H. Nielsen, A. Silman, J. Smolen, H. Yazici (2006)
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Annals of the Rheumatic Diseases, 66
K. Saag, Catherine Finney, Jeffrey Curtis, H. Paulus, Mary Elkins-Melton, R. Outman, J. Allison, S. Bridges, Jr, W. Chatham, D. Furst
American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
D. Aletaha, J. Smolen (2002)
Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.The Journal of rheumatology, 29 8
M. Soubrier, X. Puéchal, J. Sibilia, X. Mariette, O. Meyer, B. Combe, R. Flipo, D. Mulleman, F. Berenbaum, C. Zarnitsky, T. Schaeverbeke, P. Fardellone, M. Dougados (2009)
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.Rheumatology, 48 11
K. Michaud, Jodi Messer, Hyon Choi, F. Wolfe (2003)
Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.Arthritis and rheumatism, 48 10
B. Svensson, A. Boonen, K. Albertsson, D. Heijde, C. Keller, I. Hafström (2005)
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.Arthritis and rheumatism, 52 11
E. Keystone, P. Emery, C. Peterfy, P. Tak, Stanley Cohen, M. Genovese, M. Dougados, G. Burmester, M. Greenwald, T. Kvien, Sarah Williams, D. Hagerty, M. Cravets, T. Shaw (2008)
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapiesAnnals of the Rheumatic Diseases, 68
S. Wolde, F. Breedveld, B. Dijkmans, J. Hermans, J. Vandenbroucke, M. Laar, H. Markusse, M. Janssen, H. Brink (1996)
Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritisThe Lancet, 347
J. Smolen, D. Heijde, E. St.clair, P. Emery, J. Bathon, E. Keystone, R. Maini, J. Kalden, M. Schiff, D. Baker, Chenglong Han, John Han, M. Bala (2006)
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.Arthritis and rheumatism, 54 3
L. Klareskog, D. Heijde, J. Jager, A. Gough, J. Kalden, M. Malaise, E. Mola, K. Pavelka, J. Sany, L. Settas, J. Wajdula, R. Pedersen, S. Fatenejad, M. Sanda (2004)
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialThe Lancet, 363
J. Singh, R. Christensen, G. Wells, M. Suarez‐Almazor, R. Buchbinder, M. Lopez-Olivo, E. Ghogomu, P. Tugwell (2010)
Biologics for rheumatoid arthritis: an overview of Cochrane reviews.Sao Paulo medical journal = Revista paulista de medicina, 128 5
S. Wolde, J. Hermans, F. Breedveld, B. Dijkmans (1997)
Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuationAnnals of the Rheumatic Diseases, 56
(2010)
Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis, 69
by guest
M. Rudwaleit, R. Landewé, D. Heijde, J. Listing, J. Brandt, Jürgen Braun, R. Burgos-Vargas, E. Collantes-Estévez, John Davis, B. Dijkmans, M. Dougados, P. Emery, I. Horst-Bruinsma, R. Inman, M. Khan, M. Leirisalo-Repo, S. Linden, W. Maksymowych, H. Mielants, I. Olivieri, R. Sturrock, K. Vlam, J. Sieper (2009)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisalAnnals of the Rheumatic Diseases, 68
(2009)
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, 68
L. Lard, H. Visser, I. Speyer, I. Horst-Bruinsma, A. Zwinderman, F. Breedveld, J. Hazes (2001)
Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies.The American journal of medicine, 111 6
A. Bennett, A. Rehman, E. Hensor, H. Marzo-Ortega, P. Emery, D. McGonagle (2009)
The fatty Romanus lesion: a non-inflammatory spinal MRI lesion specific for axial spondyloarthropathyAnnals of the Rheumatic Diseases, 69
R. Maini, P. Taylor, J. Szechiński, K. Pavelka, J. Broll, G. Bálint, P. Emery, F. Raemen, J. Petersen, J. Smolen, D. Thomson, T. Kishimoto (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.Arthritis and rheumatism, 54 9
J. Kirwan, J. Bijlsma, J. Bijlsma, M. Boers, B. Shea (2007)
Effects of glucocorticoids on radiological progression in rheumatoid arthritis.The Cochrane database of systematic reviews, 1
Marian Burr, H. Naseem, A. Hinks, S. Eyre, L. Gibbons, J. Bowes, A. Wilson, James Maxwell, Ann Morgan, Paul Emery, S. Steer, Lynne Hocking, David Reid, P. Wordsworth, Pille Harrison, W. Thomson, Jane Worthington, Birac Consortium, A. Barton (2010)
PADI 4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population
P. Emery, E. Keystone, H. Tony, A. Cantagrel, R. Vollenhoven, A. Sánchez, E. Alecock, J. Lee, J. Kremer (2008)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAnnals of the Rheumatic Diseases, 67
J. Bathon, Richard Martin, R. Fleischmann, J. Tesser, M. Schiff, E. Keystone, M. Genovese, M. Wasko, L. Moreland, A. Weaver, J. Markenson, B. Finck (2000)
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.The New England journal of medicine, 343 22
G. Haugeberg, A. Bennett, D. McGonagle, P. Emery, H. Marzo-Ortega (2010)
Bone loss in very early inflammatory back pain in undifferentiated spondyloarthropathy: a 1-year observational studyAnnals of the Rheumatic Diseases, 69
(2009)
Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis, 68
A. Lehman, J. Esdaile, A. Klinkhoff, E. Grant, A. Fitzgerald, J. Canvin (2005)
A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.Arthritis and rheumatism, 52 5
T. Möttönen, P. Hannonen, M. Leirisalo-Repo, M. Nissilä, H. Kautiainen, M. Korpela, L. Laasonen, H. Julkunen, R. Luukkainen, K. Vuori, L. Paimela, H. Blåfield, M. Hakala, K. Ilva, U. Yli-Kerttula, K. Puolakka, P. Järvinen, M. Hakola, H. Piirainen, J. Ahonen, Ilppo Pälvimäki, S. Forsberg, K. Koota, C. Friman (1999)
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trialThe Lancet, 353
R. Yood (2002)
Guidelines for the management of rheumatoid arthritis: 2002 Update.Arthritis and rheumatism, 46 2
James Robinson, J. Barrett, John Taylor, Marc Naven, D. Corscadden, A. Barton, A. Wilson, P. Emery, J. Isaacs, A. Morgan (2009)
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive diseaseAnnals of the Rheumatic Diseases, 69
National Collaborating Centre for Chronic Conditions. Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults. London: Royal College of Physicians
T. Pincus, Y. Yazici, T. Sokka, D. Aletaha, J. Smolen (2003)
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.Clinical and experimental rheumatology, 21 5 Suppl 31
G. Haugeberg, P. Conaghan, M. Quinn, P. Emery (2009)
Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled studyAnnals of the Rheumatic Diseases, 68
R. Alten, C. Zerbini, S. Jeka, F. Irazoque, Faruq Khatib, P. Emery, A. Bertasso, M. Rabbia, J. Caulfield (2009)
Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapyAnnals of the Rheumatic Diseases, 69
C. Salliot, D. Heijde (2008)
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature researchAnnals of the Rheumatic Diseases, 68
G. Kobelt, B. Jönsson (2007)
The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatmentsThe European Journal of Health Economics, 8
(2005)
Diagnostic and prognostic signifi cance of autoantibodies in early rheumatoid arthritis
(2002)
Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial, 137
Pradip Nandi, G. Kingsley, D. Scott (2008)
Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritisCurrent Opinion in Rheumatology, 20
(2010)
Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
(2010)
Recommendations Ann Rheum Dis
D. Lacaille, A. Anis, D. Guh, J. Esdaile (2005)
Gaps in care for rheumatoid arthritis: a population study.Arthritis and rheumatism, 53 2
Angela Zink and Désirée van der Heijde
Josef Smolen, T. Sokka, T. Pincus, Breedveld Fc (2003)
A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures.Clinical and experimental rheumatology, 21 5 Suppl 31
L. Moreland, K. Sewell, D. Trentham, R. Bucy, W. Sullivan, R. Schrohenloher, R. Shmerling, K. Parker, W. Swartz, T. Woodworth (1995)
Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.Arthritis and rheumatism, 38 9
J. O'dell, C. Haire, Nils Erikson, W. Drymalski, William Palmer, P. Eckhoff, Vernon Garwood, P. Maloley, L. Klassen, S. Wees, Harry Klein, G. Moore (1996)
Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.The New England journal of medicine, 334 20
D. McCarty (1990)
Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians.The Journal of rheumatology, 17 9
M. Dougados, B. Combe, A. Cantagrel, P. Goupille, P. Olive, M. Schattenkirchner, S. Meusser, L. Paimela, R. Rau, H. Zeidler, M. Leirisalo-Repo, K. Peldán (1999)
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single componentsAnnals of the Rheumatic Diseases, 58
(2005)
Superior effi cacy of combination therapy for rheumatoid arthritis : fact or fi ction ?
S. Berney (2008)
Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized TrialYearbook of Medicine, 2008
R. Tan, L. Gibbons, C. Potter, K. Hyrich, A. Morgan, A. Wilson, J. Isaacs, A. Barton (2010)
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatmentAnnals of the Rheumatic Diseases, 69
L. Schipper, J. Fransen, P. Barrera, A. Broeder, P. Riel (2009)
Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?Rheumatology, 48 10
(2010)
06_annrheumdis126532.indd 973 06_annrheumdis126532.indd 973 8
D. Furst, F. Breedveld, J. Kalden, J. Smolen, G. Burmester, J. Sieper, P. Emery, E. Keystone, M. Schiff, P. Mease, P. Riel, R. Fleischmann, M. Weisman, M. Weinblatt (2007)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007Annals of the Rheumatic Diseases, 66
Michael Ward, J. Leigh, J. Leigh, James Fries (1993)
Progression of functional disability in patients with rheumatoid arthritis. Associations with rheumatology subspecialty care.Archives of internal medicine, 153 19
M. Dougados, N. Betteridge, G. Burmester, L. Euller‐Ziegler, F. Guillemin, J. Hirvonen, Jon Lloyd, S. Ozen, J. Silva, P. Emery, J. Kalden, T. Kvien, M. Matucci-Cerinic, J. Smolen (2004)
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committeesAnnals of the Rheumatic Diseases, 63
eter, L. E, Ipsky, Esiree, M. M.F., Van Der, Eijde, Aniel, F. E, Urst, Erdinand, B. C., Reedveld, Oachim, K. R., Alden, Osef, S. S., Molen, Ichael, Eisman, Aul, Mery, regory, H. R., Arriman, Avinder, M. N, Aini (2000)
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.The New England journal of medicine, 343 22
(2004)
Benefi t of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis
D. Aletaha, J. Funovits, F. Breedveld, John Sharp, Oscar Segurado, J. Smolen (2009)
Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment.Arthritis and rheumatism, 60 5
Katrina Donahue, G. Gartlehner, D. Jonas, L. Lux, P. Thieda, B. Jonas, R. Hansen, L. Morgan, K. Lohr (2008)
Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid ArthritisAnnals of Internal Medicine, 148
N. Nishimoto, J. Hashimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi, N. Murata, D. Heijde, T. Kishimoto (2007)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnnals of the Rheumatic Diseases, 66
J. Spalding, J. Hay (2012)
Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid ArthritisPharmacoEconomics, 24
P. Emery, F. Breedveld, S. Hall, P. Durez, D. Chang, D. Robertson, Amitabh Singh, R. Pedersen, A. Koenig, B. Freundlich (2008)
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trialThe Lancet, 372
J. Smolen, D. Aletaha, M. Koeller, M. Weisman, P. Emery (2007)
New therapies for treatment of rheumatoid arthritisThe Lancet, 370
M. Calguneri, S. Pay, Z. Caliskaner, S. Apraş, S. Kiraz, I. Ertenli, Cobankara (1999)
Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.Clinical and experimental rheumatology, 17 6
J. Callen (1996)
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritisJournal of The American Academy of Dermatology, 35
D. Heijde, P. Riel, M. Leeuwen, M. Hof, M. Rijswijk, L. Putte (1992)
Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients.British journal of rheumatology, 31 8
E. Molenaar, A. Voskuyl, B. Dijkmans (2002)
Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission.The Journal of rheumatology, 29 2
E. Yelin, L. Wanke (1999)
An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline.Arthritis and rheumatism, 42 6
S. Gorter, J. Bijlsma, M. Cutolo, J. Gómez-Reino, M. Kouloumas, J. Smolen, R. Landewé (2010)
Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisAnnals of the Rheumatic Diseases, 69
J. Kekow, R. Moots, Paul Emery, P. Durez, A. Koenig, A. Singh, Ronald Pedersen, D. Robertson, B. Freundlich, Reiko Sato (2009)
Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trialAnnals of the Rheumatic Diseases, 69
J. Hoes, J. Jacobs, M. Boers, D. Boumpas, F. Buttgereit, N. Caeyers, E. Choy, M. Cutolo, J. Silva, G. Esselens, L. Guillevin, I. Hafström, J. Kirwan, J. Rovenský, A. Russell, K. Saag, B. Svensson, R. Westhovens, H. Zeidler, J. Bijlsma (2007)
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseasesAnnals of the Rheumatic Diseases, 66
J. Smolen, M. Weinblatt (2008)
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?Annals of the Rheumatic Diseases, 67
J. Fransen, H. Moens, I. Speyer, P. Riel (2005)
Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trialAnnals of the Rheumatic Diseases, 64
M. Weinblatt, J. Kremer, A. Bankhurst, K. Bulpitt, R. Fleischmann, Robert Fox, C. Jackson, M. Lange, D. Burge (1999)
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.The New England journal of medicine, 340 4
M. Genovese, F. Breedveld, P. Emery, Stanley Cohen, E. Keystone, E. Matteson, Y. Baptiste, A. Chai, L. Burke, W. Reiss, M. Sweetser, T. Shaw (2009)
Safety of biological therapies following rituximab treatment in rheumatoid arthritis patientsAnnals of the Rheumatic Diseases, 68
M. Buch, David Boyle, S. Rosengren, B. Saleem, R. Reece, L. Rhodes, A. Radjenovic, A. English, Haiqing Tang, G. Vratsanos, P. O'connor, G. Firestein, P. Emery (2008)
Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot studyAnnals of the Rheumatic Diseases, 68
S. Verstappen, J. Jacobs, J. Jacobs, M. Veen, A. Heurkens, Y. Schenk, E. Borg, A. Blaauw, J. Bijlsma (2007)
Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)Annals of the Rheumatic Diseases, 66
Withdrawal of DMARDs in patients with rheumatoid arthritis: a systematic review and meta-analysis
Y. Goekoop-Ruiterman, J. Vries-Bouwstra, C. Allaart, D. Zeben, P. Kerstens, J. Hazes, A. Zwinderman, H. Ronday, K. Han, M. Westedt, A. Gerards, J. Groenendael, W. Lems, M. Krugten, F. Breedveld, B. Dijkmans (2005)
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.Arthritis and rheumatism, 52 11
D. Heijde, P. Riel, I. Nuver-Zwart, L. Putte (1990)
Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3-year follow-upThe Lancet, 335
N. Barkham, L. Coates, H. Keen, E. Hensor, A. Fraser, A. Redmond, L. Cawkwell, P. Emery (2010)
Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitisAnnals of the Rheumatic Diseases, 69
(2009)
Association of rheumatoid factor and anti - cyclic citrullinated peptide positivity , but not carriage of shared epitope or PTPN 22 susceptibility variants , with anti - TNF response in RA
J. Hoes, J. Jacobs, S. Verstappen, J. Bijlsma, G. Heijden (2008)
Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysisAnnals of the Rheumatic Diseases, 68
F. Breedveld, M. Weisman, A. Kavanaugh, S. Cohen, K. Pavelka, R. Vollenhoven, J. Sharp, John Perez, G. Spencer-Green (2006)
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.Arthritis and rheumatism, 54 1
(1996)
The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial, 124
J. Freeston, R. Wakefield, P. Conaghan, E. Hensor, Sheena Stewart, P. Emery (2009)
A diagnostic algorithm for persistence of very early inflammatory arthritis: the utility of power Doppler ultrasound when added to conventional assessment toolsAnnals of the Rheumatic Diseases, 69
E. Molenaar, A. Voskuyl, H. Dinant, P. Bezemer, M. Boers, B. Dijkmans (2004)
Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission.Arthritis and rheumatism, 50 1
(2009)
Rituximab improved physical function and quality of life in patients with early rheumatoid arthritis: results from a randomized active comparator placebo-controlled trial of rituximab in combination with methotrexate compared to methotrexate alone in pat, 68
A. Rat, M. Boissier (2004)
Rheumatoid arthritis: direct and indirect costs.Joint, bone, spine : revue du rhumatisme, 71 6
(2010)
Association of CD 40 with rheumatoid arthritis confi rmed in a large UK case-control study
C. Gaujoux-Viala, J. Smolen, R. Landewé, M. Dougados, T. Kvien, E. Mola, M. Scholte-Voshaar, P. Riel, L. Gossec (2010)
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisAnnals of the Rheumatic Diseases, 69
Klaus Pugner, David Scott, Jeremy Holmes, Klaus Hieke (2000)
The costs of rheumatoid arthritis: an international long-term view.Seminars in arthritis and rheumatism, 29 5
M. Schoels, J. Wong, D. Scott, A. Zink, P. Richards, R. Landewé, J. Smolen, D. Aletaha (2010)
Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritisAnnals of the Rheumatic Diseases, 69
J. Gómez-Reino, L. Carmona (2006)
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year periodArthritis Research & Therapy, 8
(2006)
The comparative effi cacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis
J. Nam, K. Winthrop, R. Vollenhoven, K. Pavelka, G. Valesini, E. Hensor, G. Worthy, R. Landewé, J. Smolen, P. Emery, M. Buch (2010)
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RAAnnals of the Rheumatic Diseases, 69
(2006)
The defi nition and measurement of disease modifi cation in infl ammatory rheumatic diseases
(2004)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial, 50
D. Aletaha, J. Funovits, E. Keystone, J. Smolen (2007)
Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.Arthritis and rheumatism, 56 10
B. Saleem, H. Keen, V. Goeb, R. Parmar, S. Nizam, E. Hensor, S. Churchman, M. Quinn, R. Wakefield, P. Conaghan, F. Ponchel, P. Emery (2010)
Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?Annals of the Rheumatic Diseases, 69
C. Grigor, H. Capell, A. Stirling, A. McMahon, Peter Lock, R. Vallance, D. Porter, W. Kincaid (2004)
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trialThe Lancet, 364
D. Scott, B. Coulton, D. Symmons, A. Popert (1987)
LONG-TERM OUTCOME OF TREATING RHEUMATOID ARTHRITIS: RESULTS AFTER 20 YEARSThe Lancet, 329
S. Eyre, E. Flynn, Paul Martin, A. Hinks, A. Wilson, A. Morgan, P. Emery, S. Steer, L. Hocking, D. Reid, Pille Harrison, Paul Wordsworth, W. Thomson, Jane Worthington, A. Barton (2009)
No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohortAnnals of the Rheumatic Diseases, 69
S. Cohen, E. Hurd, J. Cush, M. Schiff, M. Weinblatt, L. Moreland, J. Kremer, M. Bear, W. Rich, D. McCabe (2002)
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.Arthritis and rheumatism, 46 3
Y. Teng, R. Verburg, K. Verpoort, G. Diepenhorst, I. Bajema, M. Tol, Els Zijde, R. Toes, T. Huizinga, J. Laar (2007)
Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case studyArthritis Research & Therapy, 9
E. Keystone, A. Kavanaugh, J. Sharp, H. Tannenbaum, Y. Hua, L. Teoh, S. Fischkoff, E. Chartash (2004)
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.Arthritis and rheumatism, 50 5
(2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, 350
K. Machold, R. Landewé, J. Smolen, T. Stamm, D. Heijde, K. Verpoort, K. Brickmann, J. Vázquez-Mellado, D. Karateev, F. Breedveld, P. Emery, T. Huizinga (2010)
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritisAnnals of the Rheumatic Diseases, 69
(2010)
Mesenchymal stem cells in rheumatoid synovium : enumeration and functional assessment in relation to synovial infl ammation level
K. Hyrich, M. Lunt, K. Watson, D. Symmons, A. Silman (2007)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.Arthritis and rheumatism, 56 1
The Eight EULAR 2012 Objectives
H. Marzo-Ortega, D. McGonagle, P. O'connor, E. Hensor, A. Bennett, Michael Green, P. Emery (2008)
Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistenceAnnals of the Rheumatic Diseases, 68
D. Aletaha, J. Funovits, J. Smolen (2008)
The importance of reporting disease activity states in rheumatoid arthritis clinical trials.Arthritis and rheumatism, 58 9
S. Wassenberg, R. Rau, P. Steinfeld, H. Zeidler (2005)
Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial.Arthritis and rheumatism, 52 11
N. Vastesaeger, Stephen Xu, D. Aletaha, E. William, S. Clair, J. Smolen (2009)
A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis.Rheumatology, 48 9
C. Haagsma, P. Riel, A. Jong, L. Putte (1997)
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.British journal of rheumatology, 36 10
(1995)
Efficacy of methotrexate in rheumatoid arthritis, 34
(2010)
The American College of Rheumatology / European League Against Rheumatism Classifi cation and Diagnostic Criteria for Rheumatoid Arthritis
S. Cohen, P. Emery, M. Greenwald, M. Dougados, R. Furie, M. Genovese, E. Keystone, J. Loveless, G. Burmester, M. Cravets, E. Hessey, T. Shaw, M. Totoritis (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.Arthritis and rheumatism, 54 9
S. Jarrett, F. Sivera, L. Cawkwell, H. Marzo-Ortega, D. McGonagle, E. Hensor, L. Coates, P. O'connor, Alexander Fraser, P. Conaghan, P. Emery (2008)
MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxibAnnals of the Rheumatic Diseases, 68
G. Jones, A. Sebba, J. Gu, M. Lowenstein, A. Calvo, J. Gómez-Reino, D. Siri, M. Tomšič, E. Alecock, T. Woodworth, M. Genovese (2009)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnnals of the Rheumatic Diseases, 69
A. Heide, J. Jacobs, J. Bijlsma, A. Heurkens, Christina Booma-Frankfort, M. Veen, H. Haanen, D. Hofman (1996)
The Effectiveness of Early Treatment with Second-Line Antirheumatic DrugsAnnals of Internal Medicine, 124
K. Visser, W. Katchamart, Estíbaliz Loza, Ja Martinez-Lopez, C. Salliot, J. Trudeau, C. Bombardier, L. Carmona, D. Heijde, Jw Bijlsma, Dt Boumpas, Helena Canhão, Cj Edwards, Hamuryudan, T. Kvien, B. Leeb, E. Martín-Mola, H. Mielants, U. Müller-Ladner, Gillian Murphy, Mikkel Ǿstergaard, Ia Pereira, Cesar Ramos-Remus, Gabriele Valentini, J. Zochling, M. Dougados (2008)
Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E InitiativeAnnals of the Rheumatic Diseases, 68
J. Kirwan (1995)
The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group.The New England journal of medicine, 333 3
M. Dougados, P. Emery, E. Lemmel, Rodriguez Serna, C. Zerbini, S. Brin, P. Riel (2003)
Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.The Journal of rheumatology, 30 12
L. Criswell, C. Such, E. Yelin (1997)
Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.The Journal of rheumatology, 24 12
V. Nell, K. Machold, T. Stamm, G. Eberl, H. Heinzl, M. Uffmann, J. Smolen, G. Steiner (2005)
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritisAnnals of the Rheumatic Diseases, 64
G. Plosker, Katherine Croom (2005)
Sulfasalazine: a review of its use in the management of rheumatoid arthritis.Drugs, 65 13
J. Smolen, D. Aletaha, J. Bijlsma, F. Breedveld, D. Boumpas, G. Burmester, B. Combe, M. Cutolo, M. Wit, M. Dougados, P. Emery, A. Gibofsky, J. Gómez-Reino, B. Haraoui, J. Kalden, E. Keystone, T. Kvien, I. McInnes, E. Martı́n-Mola, C. Montecucco, M. Schoels, D. Heijde (2010)
Treating rheumatoid arthritis to target: recommendations of an international task forceAnnals of the Rheumatic Diseases, 69
V. Bejarano, P. Conaghan, S. Proudman, M. Buch, A. Brown, P. Emery (2009)
Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritisAnnals of the Rheumatic Diseases, 68
S. Eyre, A. Hinks, E. Flynn, Paul Martin, A. Wilson, J. Maxwell, A. Morgan, P. Emery, S. Steer, L. Hocking, D. Reid, Pille Harrison, P. Wordsworth, W. Thomson, Jane Worthington, A. Barton (2009)
Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK populationAnnals of the Rheumatic Diseases, 69
R. Westhovens, M. Robles, A. Ximenes, Savithree Nayiager, J. Wollenhaupt, P. Durez, J. Gómez-Reino, W. Grassi, B. Haraoui, W. Shergy, Sung-Hwan Park, H. Genant, C. Peterfy, J. Becker, A. Covucci, Roy Helfrick, J. Bathon (2009)
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnnals of the Rheumatic Diseases, 68
M. Boers, A. Verhoeven, H. Markusse, M. Laar, R. Westhovens, J. Denderen, D. Zeben, B. Dijkmans, A. Peeters, P. Jacobs, H. Brink, H. Schouten, D. Heijde, A. Boonen, S. Linden (1997)
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritisThe Lancet, 350
A. Finckh, A. Ciurea, L. Brulhart, B. Möller, U. Walker, D. Courvoisier, D. Kyburz, J. Dudler, C. Gabay, on Arthritis (2009)
Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?Annals of the Rheumatic Diseases, 69
D. Aletaha, R. Landewé, T. Karonitsch, J. Bathon, M. Boers, C. Bombardier, S. Bombardieri, Hyon Choi, B. Combe, M. Dougados, P. Emery, J. Gómez-Reino, E. Keystone, G. Koch, T. Kvien, E. Martı́n-Mola, M. Matucci-Cerinic, K. Michaud, J. O'dell, H. Paulus, T. Pincus, P. Richards, L. Simon, J. Siegel, J. Smolen, T. Sokka, V. Strand, P. Tugwell, D. Heijde, P. Riel, S. Vlad, R. Vollenhoven, M. Ward, M. Weinblatt, G. Wells, B. White, F. Wolfe, Bin Zhang, A. Zink, D. Felson (2008)
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.Arthritis and rheumatism, 59 10
A. Rat, V. Henegariu, M. Boissier (2004)
Do primary care physicians have a place in the management of rheumatoid arthritis?Joint, bone, spine : revue du rhumatisme, 71 3
M. Genovese, J. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, C. Birbara, J. Box, K. Natarajan, I. Nuamah, Tracy Li, R. Aranda, D. Hagerty, M. Dougados (2005)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.The New England journal of medicine, 353 11
M. Suarez‐Almazor, E. Belseck, B. Shea, J. Homik, G. Wells, P. Tugwell (2000)
Antimalarials for treating rheumatoid arthritis.The Cochrane database of systematic reviews, 4
J. Hamilton, I. McInnes, E. Thomson, D. Porter, J. Hunter, R. Madhok, H. Capell (2001)
Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived areaAnnals of the Rheumatic Diseases, 60
(2009)
Addition of infl iximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
K. Watson, D. Symmons, I. Griffiths, A. Silman (2005)
The British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 64
L. Doward, S. McKenna, D. Whalley, A. Tennant, B. Griffiths, P. Emery, D. Veale (2008)
The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosusAnnals of the Rheumatic Diseases, 68
P. Emery, F. Breedveld, M. Dougados, J. Kalden, M. Schiff, J. Smolen (2002)
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guideAnnals of the Rheumatic Diseases, 61
G. Gilworth, Paul Emery, L. Gossec, T. Vlieland, F. Breedveld, A. Hueber, G. Schett, A. Tennant (2008)
Adaptation and cross-cultural validation of the rheumatoid arthritis work instability scale (RA–WIS)Annals of the Rheumatic Diseases, 68
J. Smolen, Chenglong Han, D. Heijde, P. Emery, J. Bathon, E. Keystone, R. Maini, J. Kalden, D. Aletaha, D. Baker, J. Han, M. Bala, E. Clair (2008)
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockadeAnnals of the Rheumatic Diseases, 68
D. Solomon, D. Bates, R. Panush, J. Katz (1997)
Costs, Outcomes, and Patient Satisfaction by Provider Type for Patients with Rheumatic and Musculoskeletal Conditions: A Critical Review of the Literature and Proposed Methodologic StandardsAnnals of Internal Medicine, 127
M. Schoels, D. Aletaha, J. Smolen, J. Bijlsma, G. Burmester, F. Breedveld, M. Cutolo, B. Combe, M. Dougados, P. Emery, J. Kalden, E. Keystone, T. Kvien, E. Martı́n-Mola, C. Montecucco, M. Wit (2009)
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008Annals of the Rheumatic Diseases, 69
J. Smolen, J. Kay, M. Doyle, R. Landewé, E. Matteson, J. Wollenhaupt, N. Gaylis, F. Murphy, J. Neal, Yiying Zhou, S. Visvanathan, E. Hsia, Mahboob Rahman (2009)
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialThe Lancet, 374
D. Furst, E. Keystone, R. Fleischmann, P. Mease, F. Breedveld, J. Smolen, J. Kalden, J. Braun, B. Bresnihan, G. Burmester, F. Benedetti, T. Dorner, P. Emery, A. Gibofsky, A. Kavanaugh, B. Kirkham, M. Schiff, J. Sieper, N. Singer, P. Riel, M. Weinblatt, M. Weisman, K. Winthrop (2009)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009Annals of the Rheumatic Diseases, 69
A. Everdingen, J. Jacobs, D. Reesema, J. Bijlsma (2002)
Low-Dose Prednisone Therapy for Patients with Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialAnnals of Internal Medicine, 136
T. Möttönen, P. Hannonen, M. Boers (1999)
Combination DMARD therapy including corticosteroids in early rheumatoid arthritis.Clinical and experimental rheumatology, 17 6 Suppl 18
P. Emery, R. Vollenhoven, M. Østergaard, E. Choy, B. Combe, W. Graninger, K. Krueger, M. Matucci-Cerinic, F. Navarro, P. Riel, L. Settas, S. Steinfeld (2009)
Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across EuropeAnnals of the Rheumatic Diseases, 68
Annals of the Rheumatic Diseases – Unpaywall
Published: May 6, 2010
Access the full text.
Sign up today, get DeepDyve free for 14 days.